Jenum, Synne http://orcid.org/0000-0001-8187-775X
Tonby, Kristian
Rueegg, Corina S. http://orcid.org/0000-0003-3720-4659
Rühwald, Morten
Kristiansen, Max P. http://orcid.org/0000-0003-1361-3634
Bang, Peter http://orcid.org/0000-0001-6028-0911
Olsen, Inge Christoffer http://orcid.org/0000-0001-6889-5873
Sellæg, Kjersti http://orcid.org/0000-0002-7603-419X
Røstad, Kjerstin
Mustafa, Tehmina http://orcid.org/0000-0001-9822-1191
Taskén, Kjetil http://orcid.org/0000-0003-2841-4697
Kvale, Dag
Mortensen, Rasmus http://orcid.org/0000-0003-0177-3032
Dyrhol-Riise, Anne Ma http://orcid.org/0000-0003-4009-4032
Funding for this research was provided by:
same as corresponding author
Norges Forskningsråd (GlobVac no 234493)
Ministry of Health | Statens Serum Institut
Article History
Received: 18 March 2021
Accepted: 25 October 2021
First Online: 22 November 2021
Competing interests
: The authors have no competing interests or other interests that might be perceived to influence the results and/or discussion reported in this paper. M.R., M.K., P.B., and R.M. are employees at SSI that develop the H56:IC31 vaccine. They are not inventors of patents and have no financial interests.